The association of NF-κB signaling with intestinal inflammation-related pathologies is supported by the NF-κB-inhibiting properties of drugs used in the treatment of IBD, such as aminosalicylates [73,74]. This evidence concerns the gene NFKB1 and inflammatory bowel disease.